IDEXX Laboratories, Inc. - 10-Q Summary (Period Ended Sept 30, 2008)
Business Context and Reporting Period
This is a Quarterly Report on Form 10-Q for IDEXX Laboratories, Inc., a provider of diagnostic products and services for the veterinary, production animal, water quality, and human medical markets. The reporting period covers the three and nine months ended September 30, 2008. The company operates primarily through three reportable segments: Companion Animal Group (CAG), Water, and Production Animal Segment (PAS).
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sept 30, 2008 | 9 Months Ended Sept 30, 2008 |
|---|---|---|
| Total Revenue | $251,093 | $780,737 |
| Gross Profit | $128,149 (51.0% margin) | $409,245 (52.4% margin) |
| Net Income | $25,699 | $92,614 |
| Diluted EPS | $0.42 | $1.48 |
| Cash & Equivalents | $84,586 | $84,586 (Balance Sheet) |
| Operating Cash Flow (9mo) | N/A | $109,814 |
| Short-term Debt | $163,942 | $163,942 (Balance Sheet) |
| Working Capital | $45,627 | $45,627 (Balance Sheet) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 9.5% year-over-year for the quarter and 15.2% for the nine-month period. Growth was driven by organic demand, acquisitions (including VetLab S.L. in Spain), and favorable currency impacts (approx. 2% for the quarter, 4% for the nine months).
- Profitability: Net income for the quarter remained flat at $25.7M compared to the prior year, while nine-month net income grew 35% to $92.6M. Operating income increased 8% for the quarter and 37% for the nine months.
- Debt & Liquidity: Short-term debt increased significantly to $163.9M (from $72.2M at year-end 2007) due to increased borrowings under the revolving credit facility to fund share repurchases and acquisitions. Cash and cash equivalents increased to $84.6M.
- Segment Performance: CAG revenue grew 9.4% (quarter) and 15.2% (nine months). Water revenue grew 16.6% (quarter) and 17.1% (nine months). PAS revenue grew 2.4% (quarter) and 14.3% (nine months).
Guidance, Outlook, and Risks
- Pharmaceutical Divestiture: On October 17, 2008, the company entered an agreement to sell its ACAREXX and SURPASS pharmaceutical products and a product under development. Proceeds are projected at approximately $8 million, with the transaction expected to close in Q4 2008.
- Currency Risk: A strengthening U.S. dollar since August 2008 has negatively impacted international revenues and margins. A 1% strengthening of the dollar is estimated to decrease Q4 revenue by $1.0 million and operating income by $0.1 million (net of hedges).
- Regulatory Changes: The company anticipates losing sales of Filta-Max products in England and Wales starting Q4 2008 due to the discontinuation of mandatory Cryptosporidium testing. Additionally, EU changes to BSE testing regimes effective Jan 1, 2009, are expected to reduce sales of post-mortem BSE tests.
- Capital Allocation: The company continues an aggressive share repurchase program, spending $122.4M on treasury stock in the first nine months of 2008. Capital expenditures for 2008 are estimated at $100M, including $40M for headquarters expansion.
- Legal Proceedings: The company is defending an appeal by Cyntegra, Inc. regarding antitrust claims; the trial court previously granted summary judgment in IDEXX's favor.
Investor Verification Checklist
- Verify the impact of the strengthening U.S. dollar on Q4 and full-year 2008 margins, given the 41% international revenue exposure.
- Confirm the timeline and final proceeds of the pharmaceutical product sale (ACAREXX/SURPASS) and the restructuring of the remaining pharma business.
- Monitor the effect of the expiration of the federal research and experimentation tax credit (retroactively extended to Dec 31, 2009) on the effective tax rate for the full year.
- Assess the impact of distributor inventory levels on reported revenue growth, as fluctuations may not reflect underlying end-user demand.
- Review the status of the Cyntegra antitrust appeal and potential financial exposure.